Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 4/20 | 0.41 |
| ▸ | DPP4 | P27487 | 5/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.40 |
| ▸ | FAP | Q12884 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 3/20 | 0.39 |
| ▸ | XPNPEP2 | O43895 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30203686 | 0.94 | DPP4 (0.44) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6681470 | 0.88 | ACE (0.51) | ACEREN | |
| SCHEMBL6681472 | 0.88 | ACE (0.51) | ACEREN | |
| SCHEMBL30899064 | 0.88 | ACE (0.51) | ACEREN | |
| SCHEMBL28246424 | 0.84 | PREP (0.44) | — | |
| SCHEMBL28246420 | 0.84 | PREP (0.44) | — | |
| SCHEMBL28246422 | 0.84 | PREP (0.44) | — | |
| SCHEMBL14673291 | 0.82 | CAPN1 (0.60) | CAPN1CTSB | |
| SCHEMBL20477645 | 0.82 | CAPN1 (0.60) | CAPN1CTSB | |
| SCHEMBL14673292 | 0.82 | CAPN1 (0.60) | CAPN1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3362080-A1 | PHARMACEUTICAL COMBINATION OF AN ATYPICAL ANTIPSYCHOTIC AND AN NMDA MODULATOR FOR THE TREATMENT OF SCHIZOPHRENIA,BIPOLAR DISORDER, COGNITIVE IMPAIRMENT AND MAJOR DEPRESSIVE DISORDER | Northwestern University (US) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017066590-A1 | PHARMACEUTICAL COMBINATION OF AN ATYPICAL ANTIPSYCHOTIC AND AN NMDA MODULATOR FOR THE TREATMENT OF SCHIZOPHRENIA,BIPOLAR DISORDER, COGNITIVE IMPAIRMENT AND MAJOR DEPRESSIVE DISORDER | NORTHWESTERN UNIVERSITY (US) | 2017-04-20 | — | — | WO | disclosed |
| EP-2771021-A2 | NMDA RECEPTOR MODULATORS AND USES THEREOF | North Western University (US) | 2014-09-03 | — | — | EP | disclosed |
| WO-2013063120-A2 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY (US) | 2013-05-02 | — | — | WO | disclosed |